Becton Dickinson and Company (BDX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Becton Dickinson and Company.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 165.60 $ — 36% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 8.8% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 16
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | 12.56 | 12.00 – 12.65 | 19,214 | -12.8% | 14 |
| 09/30/2027 | 13.46 | 13.04 – 14.03 | 19,723 | 7.2% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 3.14 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.04 | 8.20 | 5,168 | 9.80 | 5.90 | 693 | 588 |
| 2025: Q1 | 1.07 | -42.40 | 5,272 | 4.50 | 5.80 | 164 | 35 |
| 2025: Q2 | 1.99 | 18.50 | 5,509 | 10.40 | 10.40 | 1,219 | 1,045 |
| 2025: Q3 | 1.72 | 24.70 | 5,890 | 8.30 | 8.40 | 1,354 | 1,002 |
| 2025: Q4 | 1.34 | 28.40 | 5,252 | 1.60 | 7.30 | 657 | 549 |
| 2026: Q1 | -1.11 | -204.10 | 4,714 | -10.60 | -6.60 | 671 | 546 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 12,483 | 1,430 | 976 | 4.49 | 2,559 | 7,634 | 25,586 |
| 2017 | 12,093 | 1,522 | 1,100 | 4.92 | 2,550 | 12,948 | 37,734 |
| 2018 | 15,983 | 1,509 | 311 | 1.18 | 2,865 | 20,994 | 53,904 |
| 2019 | 17,290 | 1,760 | 1,233 | 4.49 | 3,330 | 21,082 | 51,842 |
| 2020 | 16,074 | 912 | 874 | 3.09 | 3,539 | 23,765 | 54,012 |
| 2021 | 19,131 | 2,250 | 2,092 | 7.16 | 4,647 | 23,677 | 53,880 |
| 2022 | 18,870 | 2,282 | 1,779 | 6.19 | 2,633 | 25,282 | 52,934 |
| 2023 | 19,372 | 2,111 | 1,484 | 5.15 | 2,989 | 25,797 | 52,780 |
| 2024 | 20,178 | 2,397 | 1,705 | 5.86 | 3,798 | 25,889 | 57,286 |
| 2025 | 21,839 | 2,578 | 1,678 | 5.84 | 3,430 | 25,390 | 55,325 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Becton, Dickinson and Company entwickelt, fertigt und verkauft weltweit medizinische Verbrauchsmaterialien, Geräte, Laborausrüstung und Diagnostikprodukte für Gesundheitseinrichtungen, Ärzte, Life-Science-Forscher, klinische Labore, die Pharmaindustrie und die Öffentlichkeit. Es ist in mehreren Segmenten tätig.
| Employees | 60,000 |
|---|---|
| Headquarters | Franklin Lakes, NJ |
| Address | 1 Becton Drive, 07417-1880 Franklin Lakes, United States |
| Phone | 201 847 6800 |
| Website | bd.com |
| IPO Date | 1. Jan 1987 |
| ISIN | US0758871091 |
| Stock Split | 1272:1000 on 02/10/2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Thomas E. Polen Jr. | President, CEO & Chairman | 1973 |
| Michael C. Feld | Executive VP & Chief Revenue Officer | 1981 |
| Vitor Roque | Executive VP & CFO | 1983 |
| Elizabeth McCombs | Executive VP & CTO | 1977 |
| Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior VP & Chief Scientific Officer | – |
| Denise Russell Fleming | Executive Vice President & Chief Information Officer | 1971 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 27. Jul 2026 | Feld Michael | EVP, Chief Revenue Officer | Sell | 75 | 157.13 | 11,785 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.